Cancer Chemotherapy and Pharmacology

, Volume 82, Issue 5, pp 777–785 | Cite as

A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity

  • Soo Jie Chung
  • Sung-Yoon Kang
  • Rae-Young Kang
  • Young-Chan Kim
  • Kyung-Hun Lee
  • Tae-Yong Kim
  • Sae-Won Han
  • Hye-Ryun KangEmail author
Original Article



Desensitization is a safe alternative for patients with hypersensitivity reactions (HSRs) to platinum-based chemotherapeutic agents and widely used in real practice by employing stepwise administration of multiple serial dilutions of the culprit drugs. However, its labor-intensive nature has required a simpler protocol that is easier to prepare and perform.


We performed an observational study of patients with platinum HSR who underwent a new non-dilution one-bag desensitization protocol. Premedication consisted of Montelukast as well as H1 and H2 blockers. The outcomes and safety profiles of a new protocol were assessed.


A total of 36 patients were recruited (oxaliplatin 23, carboplatin 9, and cisplatin 4) and the most common grade of HSR presented was grade 2 (61.1%), followed by grade 3 (25%), and grade 1 (13.9%). Of 175 desensitization procedures, all cases were successfully completed in re-administration of culprit chemotherapeutic platinum agents; 146 (83.4%) had no breakthrough reactions (BTRs) while 29 (16.6%) did. Most BTRs were mild reactions (grade 1, 51.7%) or moderate reactions (grade 2, 44.8%) of Brown’s Scale. Although there was one case of asymptomatic mild hypotension (grade 3, 3.5%), categorized as severe reaction, dyspnea, desaturation, and anaphylaxis did not occur. The proportion of severe HSRs was significantly lower than that of initial HSRs (3.5% vs. 25%, P = 0.0167).


The new non-dilution desensitization protocol was safe and effective for re-administration of culprit platinum agents in patients with a history of HSRs. Therefore, this new protocol can be used as an alternative to existing protocols using multiple serial dilutions.


Drug hypersensitivity Antineoplastic agents Desensitization Immunologic Platinum Drug-related side effects and adverse reactions 



Area under the curve


Breakthrough reaction


Hypersensitivity reaction



This research was supported by a Grant from Ministry of Food and Drug Safety to the regional pharmacovigilance center in 2017.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

280_2018_3662_MOESM1_ESM.docx (31 kb)
Supplementary material 1 (DOCX 31 KB)


  1. 1.
    Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378CrossRefGoogle Scholar
  2. 2.
    Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573CrossRefGoogle Scholar
  3. 3.
    Miyamoto S, Okada R, Ando K (2015) Platinum hypersensitivity and desensitization. Jpn J Clin Oncol 45(9):795–804CrossRefGoogle Scholar
  4. 4.
    Caiado J, Picard M (2014) Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep 14(8):1–12CrossRefGoogle Scholar
  5. 5.
    Sliesoraitis S, Chikhale P (2005) Carboplatin hypersensitivity. Int J Gynecol Cancer 15(1):13–18CrossRefGoogle Scholar
  6. 6.
    Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L (2009) Role of oxaliplatin in the treatment of colorectal cancer. Therap Clin Risk Manag 5:229CrossRefGoogle Scholar
  7. 7.
    Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. The Oncologist 5(1):26–35CrossRefGoogle Scholar
  8. 8.
    Network NCC (2017) NCCN clinical practice guidelines in oncology-ovarian cancer including fallopian tube cancer and primary peritoneal cancer (Version 2.2017)Google Scholar
  9. 9.
    Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574–580CrossRefGoogle Scholar
  10. 10.
    Li Q, Cohn D, Waller A, Backes F, Copeland L, Fowler J, Salani R, O’Malley D (2014) Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. Gynecol Oncol 135(1):90–94CrossRefGoogle Scholar
  11. 11.
    Brown SG (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114(2):371–376CrossRefGoogle Scholar
  12. 12.
    Lee C-W, Matulonis UA, Castells MC (2005) Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99(2):393–399CrossRefGoogle Scholar
  13. 13.
    Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(6):1262–1267. e1261CrossRefGoogle Scholar
  14. 14.
    Madrigal-Burgaleta R, Berges-Gimeno M, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, Gomez de Salazar E, Alvarez-Cuesta E (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68(7):853–861CrossRefGoogle Scholar
  15. 15.
    Wong JT, Ling M, Patil S, Banerji A, Long A (2014) Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2(1):40–45CrossRefGoogle Scholar
  16. 16.
    Nozawa H, Muto Y, Yamada Y (2008) Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer. Clin Therap 30(6):1160–1165CrossRefGoogle Scholar
  17. 17.
    Park H, Lee J, Kim S, Kim S, Park K, Lee C, Kang B, Beom S, Shin S, Jung M (2016) A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions: a necessary and useful approach. J Investig Allergol Clin Immunol 26(3):168–176CrossRefGoogle Scholar
  18. 18.
    Confino-Cohen R, Fishman A, Altaras M, Goldberg A (2005) Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 104(3):640–643CrossRefGoogle Scholar
  19. 19.
    Cortijo-Cascajares S, Nacle-López I, García-Escobar I, Aguilella-Vizcaíno MJ, Herreros-de-Tejada A, Castro HC-F, Calleja-Hernández M-Á (2013) Effectiveness of oxaliplatin desensitization protocols. Clin Transl Oncol 15(3):219–225CrossRefGoogle Scholar
  20. 20.
    Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y, Yamaguchi S, Fujiwara K, Negoro S (2015) 4-Step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol 20(3):566–573CrossRefGoogle Scholar
  21. 21.
    Okayama T, Ishikawa T, Sugatani K, Yoshida N, Kokura S, Matsuda K, Tsukamoto S, Ihara N, Kuriu Y, Nakanishi M (2015) Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol. Clin Therap 37(6):1259–1269CrossRefGoogle Scholar
  22. 22.
    Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi D-A, Azodi M, Santin A, Schwartz PE, Ratner ES (2017) Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Gynecol Oncol 144(1):77–82CrossRefGoogle Scholar
  23. 23.
    Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK (2001) Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82(3):550–558CrossRefGoogle Scholar
  24. 24.
    Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41(15):2262–2267CrossRefGoogle Scholar
  25. 25.
    Lee S-Y, Kang H-R, Song W-J, Lee K-H, Han S-W, Cho SH (2014) Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemother Pharmacol 73(5):1021–1029CrossRefGoogle Scholar
  26. 26.
    Sohn K-H, Kang D-Y, Kim J-Y, Lee S-Y, Lee K-H, Han S-W, Kang H-R (2018) Incidence and risk of oxaliplatin-induced hypersensitivity in patients with asymptomatic prior exposure: a prospective observational study. J Allergy Clin Immunol Pract. CrossRefPubMedGoogle Scholar
  27. 27.
    Weiss M, Hug MI, Neff T, Fischer J (2000) Syringe size and flow rate affect drug delivery from syringe pumps. Can J Anesth 47(10):1031–1035CrossRefGoogle Scholar
  28. 28.
    Weiss M, Bänziger O, Neff T, Fanconi S (2000) Influence of infusion line compliance on drug delivery rate during acute line loop formation. Intensive Care Med 26(6):776–779CrossRefGoogle Scholar
  29. 29.
    Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, Ureña-Tavera A, Zamora-Verduga M, Lopez-Gonzalez P, Berges-Gimeno M (2015) Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy 70(7):784–794CrossRefGoogle Scholar
  30. 30.
    Wang AL, Patil SU, Long AA, Banerji A (2015) Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Ann Allergy Asthma Immunol 115(5):422–428CrossRefGoogle Scholar
  31. 31.
    Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, Banerji A (2012) A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 129(2):443–447CrossRefGoogle Scholar
  32. 32.
    Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, Collet E (2007) Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 119(3):726–730CrossRefGoogle Scholar
  33. 33.
    Zanotti K, Rybicki L, Kennedy A, Belinson J, Webster K, Kulp B, Peterson G, Markman M (2001) Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19(12):3126–3129CrossRefGoogle Scholar
  34. 34.
    Lee C-W, Matulonis UA, Castells MC (2004) Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 95(2):370–376CrossRefGoogle Scholar
  35. 35.
    Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter A, Santucci B, Terzoli E (2003) Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 14(3):497–498CrossRefGoogle Scholar
  36. 36.
    Markman M, Zanotti K, Kulp B, Peterson G, Markman M (2003) Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 89(3):514–516CrossRefGoogle Scholar
  37. 37.
    Bruchim I, Goldberg A, Fishman A, Confino-Cohen R (2014) Carboplatin hypersensitivity: evaluation and successful desensitization protocol. Immunotherapy 6(8):905–912CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Internal MedicineSeoul National University College of MedicineSeoulSouth Korea
  2. 2.Institute of Allergy and Clinical ImmunologySeoul National University Medical Research CenterSeoulSouth Korea
  3. 3.Department of PharmacySeoul National University College of MedicineSeoulSouth Korea
  4. 4.Cancer Research InstituteSeoul National University College of MedicineSeoulSouth Korea
  5. 5.Drug Safety Monitoring CenterSeoul National University HospitalSeoulSouth Korea

Personalised recommendations